New Drug to Prevent Hypoglycemia Enters Clinical Trials

January 7, 2021

Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, such as injectable or nasal glucagon (Baqsimi), there are currently no preventive therapies available. Canadian company Zucara Therapeutics, however, may have an answer. It is developing a once-daily therapy, called ZT-01, that restores a person with T1D’s glucagon response so that they can counter-regulate hypoglycemia.

Previously, JDRF provided funding to move Zucara beyond the “valley of death”—when discovery research is translated into a therapy or technology, but lacks the funding to make it real. In April 2020, Zucara secured the backing of a large venture capital fund to move ZT-01 into clinical trials.

Hypoglycemia is an unintended consequence of insulin therapy, and happens when one takes too much insulin. It causes sweating, fatigue, irritability and, in severe cases, seizures and/or death. It is one of the most feared and acute complications of T1D.

The first clinical trials of ZT-01 began in September, 2020, and the trial is now seeking English-speaking participants in Ontario. If these early trials are successful, ZT-01 will be much closer to approval, and to providing much-needed relief to the millions of people with T1D and their families who suffer from the fear and dangers of hypoglycemia.

In November 2020, Zucara also announced new funding to broaden development of ZT-01 for hypoglycemia in people with insulin-requiring type 2 diabetes, indicating that even more people stand to benefit from the new drug.

Interested in participating in a clinical trial of ZT-01? More information here.

 

Lets turn type one into type none